Immunotherapeutic compositions and methods of production for coronavirus

A method of providing immunotherapy to a subject in need thereof, comprising administering to the subject an immunotherapeutic composition comprising:

• A) an immune globulin prepared from pooled plasma samples, wherein the pooled plasma samples are obtained by:
• 1) obtaining a plurality of plasma samples from a plurality of plasma donors;
• 2) conducting a first assay on each plasma sample to measure total anti-SARS CoV-2 antibody titer;
• 3) selecting, based upon the first assay, plasma samples having a total anti-SARS CoV-2 antibody binding titer that is at least two-fold higher than the amount of total anti-SARS CoV-2 antibody binding titer in a control sample, wherein the control sample is a mixture of plasma samples obtained from 100 or more random human plasma donors;
• 4) conducting a second assay on each selected plasma sample from step (3) to measure SARS CoV-2 neutralizing antibody titer;
• 5) identifying, based upon the second assay, plasma samples having a neutralizing antibody titer in the lower 65% of all plasma samples assayed and excluding the identified plasma samples from further processing;
• and
• 6) pooling the non-excluded plasma samples from step (5) to generate the pooled plasma samples;
• and
• B) a pharmaceutically acceptable carrier;
• wherein the immunotherapeutic composition is administered to the subject so as to provide from about 1.5-2.0 grams of immune globulin per kilogram of the subject.